Trial · NCT04411082
Results by group42
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 42
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| IMR-687 Safety and Tolerability | TDT High Dose | Treatment emergent Adverse Events | 25 | Participants | |
| IMR-687 Safety and Tolerability | TDT Low Dose | Treatment emergent Adverse Events | 22 | Participants | |
| IMR-687 Safety and Tolerability | TDT Placebo | Treatment emergent Adverse Events | 15 | Participants | |
| IMR-687 Safety and Tolerability | NTDT High Dose | Treatment emergent Adverse Events | 18 | Participants | |
| IMR-687 Safety and Tolerability | NTDT Low Dose | Treatment emergent Adverse Events | 12 | Participants | |
| IMR-687 Safety and Tolerability | NTDT Placebo | Treatment emergent Adverse Events | 6 | Participants | |
| IMR-687 Safety and Tolerability | TDT High Dose | Treatment emergent Adverse Event related to study drug | 19 | Participants | |
| IMR-687 Safety and Tolerability | TDT Low Dose | Treatment emergent Adverse Event related to study drug | 15 | Participants | |
| IMR-687 Safety and Tolerability | TDT Placebo | Treatment emergent Adverse Event related to study drug | 8 | Participants | |
| IMR-687 Safety and Tolerability | NTDT High Dose | Treatment emergent Adverse Event related to study drug | 11 | Participants | |
| IMR-687 Safety and Tolerability | NTDT Low Dose | Treatment emergent Adverse Event related to study drug | 7 | Participants | |
| IMR-687 Safety and Tolerability | NTDT Placebo | Treatment emergent Adverse Event related to study drug | 4 | Participants | |
| IMR-687 Safety and Tolerability | TDT High Dose | Grade 3 or greater treatment emergent Adverse Event | 4 | Participants | |
| IMR-687 Safety and Tolerability | TDT Low Dose | Grade 3 or greater treatment emergent Adverse Event | 9 | Participants | |
| IMR-687 Safety and Tolerability | TDT Placebo | Grade 3 or greater treatment emergent Adverse Event | 2 | Participants | |
| IMR-687 Safety and Tolerability | NTDT High Dose | Grade 3 or greater treatment emergent Adverse Event | 4 | Participants | |
| IMR-687 Safety and Tolerability | NTDT Low Dose | Grade 3 or greater treatment emergent Adverse Event | 1 | Participants | |
| IMR-687 Safety and Tolerability | NTDT Placebo | Grade 3 or greater treatment emergent Adverse Event | 1 | Participants | |
| TDT Patients: Reduction in Red Blood Cell (RBC) Transfusion Burden With ≥33% Hematological Improvement From Week 12 to Week 24 | TDT High Dose | 2 | Participants | ||
| TDT Patients: Reduction in Red Blood Cell (RBC) Transfusion Burden With ≥33% Hematological Improvement From Week 12 to Week 24 | TDT Low Dose | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04411082/results